Hepatic Manifestations in Common Variable Immunodeficiency Associated With Mortality and Worse Hospital Outcomes in Nationwide Analysis Using National Readmission Database

全国范围内利用国家再入院数据库进行的分析显示,常见变异型免疫缺陷患者的肝脏表现与死亡率和更差的住院结局相关。

阅读:2

Abstract

BACKGROUND: Liver disease is associated with increased mortality in patients with common variable immunodeficiency (CVID), yet we lack population-level data on its impact on CVID-associated hospitalizations in the United States. OBJECTIVE: To conduct a nationwide analysis evaluating the prevalence, spectrum, clinical correlates, and outcomes of hepatic manifestations among admitted adults with CVID. METHODS: We performed a retrospective cross-sectional analysis using the National Readmission Database, part of the Healthcare Cost and Utilization Project by the Agency for Healthcare Research and Quality. International Classification of Diseases, Tenth Revision codes were used to assess hepatic complications, comorbidities, risk factors, and outcomes in CVID-associated admissions with liver involvement. RESULTS: Of 181,288 CVID-related index hospitalizations, 10% (18,823) had a codiagnosed hepatic complication, specifically hepatic steatosis (38%), cirrhosis (24%), nonalcoholic fatty liver disease (17%), portal hypertension (15%), and nodular regenerative hyperplasia (14%). CVID-associated admissions with hepatic disease had longer median lengths of stay (7 vs 5 days, P < .0001), higher in-hospital mortality (11% vs 4%, P < .0001), and higher median hospital charges ($68,114 vs $44,757, P < .0001). They also had a higher prevalence of hypertension, chronic kidney disease, diabetes, obesity, and autoimmune cytopenia (P < .0001 for all). Alcohol use, hepatitis C, and hepatitis B were strong predictors of hepatic manifestations in CVID admissions (P < .0001). Patients with CVID with nodular regenerative hyperplasia (hazard ratio, 1.3; 95% CI, 1.2-1.5; P < .0001) and portal hypertension (hazard ratio, 1.4; 95% CI, 1.2-1.5; P < .0001) had lower survival. CONCLUSIONS: CVID-associated admissions with liver disease, particularly those with nodular regenerative hyperplasia and portal hypertension, were longer, more costly, and associated with increased mortality. Further studies are needed to improve early detection and long-term outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。